Search research articles
Contact Us
Filters
Showing results (61-70 of 143) with videos related to
Page
of 15
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma
Julia Matsumoto, Brian F Kiesel, Robert A Parise, et al.
Cancer Chemotherapy and Pharmacology
|
February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
Brian S Choi, Dona B Alberti, William R Schelman, et al.
Leukemia & Lymphoma
|
April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
Rena Buckstein, John Kuruvilla, Neil Chua, et al.
Pediatric Blood & Cancer
|
July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study
Orren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
Ramesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker
Anand Joshi, Jianxia Guo, Julianne L Holleran, et al.
JCO Precision Oncology
|
February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Yiduo Hu, Azeet Narayan, Yunshan Xu, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma
Joanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Suresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 143) with videos related to
Sort By:
Page
of 15
Journal of Pharmaceutical and Biomedical Analysis
|
September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma
Julia Matsumoto, Brian F Kiesel, Robert A Parise, et al.
Cancer Chemotherapy and Pharmacology
|
February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors
Brian S Choi, Dona B Alberti, William R Schelman, et al.
Leukemia & Lymphoma
|
April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
Rena Buckstein, John Kuruvilla, Neil Chua, et al.
Pediatric Blood & Cancer
|
July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study
Orren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
Ramesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2020
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker
Anand Joshi, Jianxia Guo, Julianne L Holleran, et al.
JCO Precision Oncology
|
February 27, 2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Yiduo Hu, Azeet Narayan, Yunshan Xu, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma
Joanna M Brell, Smitha S Krishnamurthi, Milind Javle, et al.
Gynecologic Oncology
|
November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
Andrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Suresh S Ramalingam, Shivaani Kummar, John Sarantopoulos, et al.
Page
of 15